SAB Biotherapeutics is a therapeutics and immunotherapy research and development company. SAB Biotherapeutics, Inc. is a company that is involved in R&D, it is using the advancement of science and genius of nature to transform the landscape of human health. It consists of a team of scientists, researchers and professionals that use technology and tenacity to pioneer a new powerful platform for making global and personal impact.
Through the use of an advanced genetic engineering and antibody science, it is dedicated to advancing a new class of immunotherapies, by leveraging the native human immune response, with first-in-class and best-in-class potential across wide therapeutic categories that include autoimmune, inflammation, infectious disease and immune-oncology. SAB-185, is among the elite therapy candidates for COVID-19, advancing with Operation Warp Speed.
As a true innovation, its novel platform is also being developed in a rapid response capacity for future response to pandemics.
CSL Behring has provided seed funding to offset some initial development costs that were funded by SAB in good faith, responding to the global pandemic as quickly as possible.